Price Target Changed • May 19
Price target increased by 13% to €14.34 Up from €12.73, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of €14.57. Stock is up 28% over the past year. The company is forecast to post a net loss per share of €1.27 next year compared to a net loss per share of €1.85 last year. Announcement • May 15
emeis Société anonyme, Annual General Meeting, Jun 23, 2026 emeis Société anonyme, Annual General Meeting, Jun 23, 2026. Location: 112 avenue kleber, paris France Announcement • Apr 27
emeis Appoints Jean-Marc Boursier as Deputy Chief Executive Officer (Corporate Officer), Effective on July 1, 2026 emeis announced that Jean-Marc Boursier, previously Deputy Chief Executive Officer (non board), has been appointed Deputy Chief Executive Officer (corporate officer) by the Board of Directors on April 24, 2026, following a recommendation by the Chief Executive Officer. Currently Deputy Chief Executive Officer (non board) in charge of Finance, Procurement and IT, and overseeing Central Europe and Latin America, Jean-Marc Boursier will be appointed Deputy Chief Executive Officer (corporate officer) with effect from July 1, 2026. Jean-Marc Boursier joined emeis on September 1, 2024 as Group CFO, and from April 1, 2025, he was appointed Deputy Chief Executive Officer (non board) with responsibilities extended to overseeing Central Europe and Latin America. Jean-Marc Boursier is an engineer, a graduate of Télécom Sud Paris and holds a Master’s degree in Finance from HEC. He previously served as CFO and COO of the SUEZ Group. Reported Earnings • Apr 12
Full year 2025 earnings: Revenues in line with analyst expectations Full year 2025 results: Revenue: €5.90b (up 4.6% from FY 2024). Net loss: €298.0m (loss narrowed 28% from FY 2024). Revenue was in line with analyst estimates. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe. Major Estimate Revision • Apr 10
Consensus EPS estimates fall by 17% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -€0.944 to -€1.10 per share. Revenue forecast unchanged at €6.10b. Healthcare industry in France expected to see average net income growth of 22% next year. Consensus price target of €12.90 unchanged from last update. Share price was steady at €13.65 over the past week. Announcement • Apr 08
Emeis Announces Non Renewal of Term of Guillaume Pepy as Chairman of the Board of Directors emeis announced that at their meeting on April 7, 2026, the Board of Directors agreed to submit for approval at the General Meeting on June 23, 2026, the non renewal of term of Guillaume Pepy. Guillaume Pepy, Chairman of the Board of Directors since July 2022, having wished to pursue other professional projects, has not sought the renewal of his term. Announcement • Jan 15
emeis Announces Board and Committee Appointments for Isemia emeis announced that Laurent Guillot will serve as Chairman of the Supervisory Committee and Gery Robert-Ambroix as Chairman of Isemia. Major Estimate Revision • Nov 03
Consensus EPS estimates upgraded to €1.33 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€1.50 to -€1.33 per share. Revenue forecast steady at €5.88b. Healthcare industry in France expected to see average net income growth of 29% next year. Consensus price target of €12.98 unchanged from last update. Share price fell 6.3% to €13.70 over the past week. Major Estimate Revision • Oct 31
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.50 to -€1.66 per share. Revenue forecast unchanged at €5.88b. Healthcare industry in France expected to see average net income growth of 28% next year. Consensus price target of €12.98 unchanged from last update. Share price was steady at €14.31 over the past week. Announcement • Oct 21
emeis Société anonyme (ENXTPA:EMEIS) commences an Equity Buyback plan for 10% of its issued share capital, under the authorization approved on June 26, 2025. emeis Société anonyme (ENXTPA:EMEIS) commences a share repurchases on October 13, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 26, 2025. As per the mandate, the company is authorized to repurchase its own shares, such that the number of shares held by the Company at any time may not, under any circumstances, exceed 10% of the shares comprising its share capital. The maximum purchase price for shares shall be €30 (excluding transaction costs) per share. The purpose of the program is to award, directly or indirectly, some or all of the bought back shares to employees and/or corporate officers of the Company and/or the Group under the terms and conditions set out by law, including under profit-sharing plans, stock option plans, free share plans or employee share ownership plans. To deliver shares upon the exercise of rights attached to securities carrying entitlement by way of conversion, exercise, redemption, exchange, or any other means to the award of Company shares in accordance with stock market regulations. To cancel the shares by reducing the capital under the conditions provided for in the French Commercial Code. To keep some or all of the bought back shares for subsequent remittance in exchange for or as consideration in connection with any growth-related transactions or any other transaction authorized pursuant to the regulations in force. To implement any market practices that are permitted by law or by the AMF. To make a market in or ensure the liquidity of the shares through an independent investment services provider acting under a liquidity agreement that complies with the Code of Conduct approved by the AMF. The authorization is valid for a period of 18 months. Reported Earnings • Oct 05
First half 2025 earnings released: €0.85 loss per share (vs €1.71 loss in 1H 2024) First half 2025 results: €0.85 loss per share (improved from €1.71 loss in 1H 2024). Revenue: €2.91b (up 4.9% from 1H 2024). Net loss: €137.0m (loss narrowed 47% from 1H 2024). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe. Price Target Changed • Sep 30
Price target increased by 8.7% to €12.48 Up from €11.48, the current price target is an average from 5 analysts. New target price is 15% below last closing price of €14.76. Stock is up 170% over the past year. The company is forecast to post a net loss per share of €1.67 next year compared to a net loss per share of €2.62 last year. Major Estimate Revision • May 30
Consensus EPS estimates upgraded to €1.14 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€1.38 to -€1.14 per share. Revenue forecast steady at €5.88b. Healthcare industry in France expected to see average net income growth of 27% next year. Consensus price target up from €11.48 to €11.88. Share price was steady at €10.19 over the past week. Announcement • May 22
emeis Société anonyme, Annual General Meeting, Jun 26, 2025 emeis Société anonyme, Annual General Meeting, Jun 26, 2025. Location: tour coeur defence, centre de conferences, 100-110 esplanade du gaulle, la defense cedex France Major Estimate Revision • May 20
Consensus EPS estimates fall by 20% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.945 to -€1.14 per share. Revenue forecast of €5.86b unchanged since last update. Healthcare industry in France expected to see average net income growth of 27% next year. Consensus price target of €11.48 unchanged from last update. Share price fell 2.3% to €11.40 over the past week. New Risk • May 19
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €412m Forecast net loss in 3 years: €23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€23m net loss in 3 years). Shareholders have been diluted in the past year (24% increase in shares outstanding). Buy Or Sell Opportunity • May 07
Now 23% undervalued Over the last 90 days, the stock has risen 40% to €11.17. The fair value is estimated to be €14.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 82% in the next 2 years. Major Estimate Revision • Apr 23
Consensus EPS estimates fall by 38% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.807 to -€1.12 per share. Revenue forecast of €5.95b unchanged since last update. Healthcare industry in France expected to see average net income growth of 27% next year. Consensus price target up from €10.58 to €11.48. Share price fell 11% to €10.00 over the past week. Price Target Changed • Apr 17
Price target increased by 9.1% to €11.48 Up from €10.53, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €11.61. Stock is down 7.1% over the past year. Reported Earnings • Apr 17
Full year 2024 earnings released Full year 2024 results: Revenue: €5.64b (up 8.4% from FY 2023). Net loss: €412.0m (down 130% from profit in FY 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Europe. Announcement • Mar 20
emeis Société anonyme to Report Fiscal Year 2024 Results on Apr 16, 2025 emeis Société anonyme announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Apr 16, 2025 Major Estimate Revision • Feb 07
Consensus EPS estimates upgraded to €2.03 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€2.26 to -€2.03 per share. Revenue forecast steady at €5.47b. Healthcare industry in France expected to see average net income growth of 25% next year. Consensus price target down from €10.75 to €9.48. Share price rose 24% to €7.86 over the past week. Major Estimate Revision • Nov 01
Consensus EPS estimates upgraded to €1.83 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €5.63b to €5.43b. 2024 losses expected to reduce from -€741 to -€1.83 per share. Healthcare industry in France expected to see average net income growth of 26% next year. Consensus price target down from €4,674 to €11.63. Share price rose 12% to €6.09 over the past week. New Risk • Oct 21
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.5% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings are forecast to decline by an average of 106% per year for the foreseeable future. High level of non-cash earnings (21% accrual ratio). Shareholders have been substantially diluted in the past year (over 2490x increase in shares outstanding). Major Estimate Revision • Oct 10
Consensus EPS estimates upgraded to €741 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€1,351 to -€741 per share. Revenue forecast steady at €5.63b. Healthcare industry in France expected to see average net income growth of 19% next year. Consensus price target down from €11,633 to €9,003. Share price rose 9.7% to €5.76 over the past week. Reported Earnings • Oct 06
First half 2024 earnings released: €1,710 loss per share (vs €5,737 loss in 1H 2023) First half 2024 results: €1,710 loss per share (improved from €5,737 loss in 1H 2023). Revenue: €2.77b (up 9.2% from 1H 2023). Net loss: €257.0m (loss narrowed 31% from 1H 2023). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Europe. Price Target Changed • Oct 04
Price target decreased by 27% to €9,003 Down from €12,300, the current price target is an average from 3 analysts. New target price is 157,786% above last closing price of €5.70. Stock is down 100% over the past year. The company is forecast to post a net loss per share of €741 compared to earnings per share of €131 last year. Major Estimate Revision • Sep 08
Consensus EPS estimates fall by 22%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €5.45b to €5.63b. Forecast EPS reduced from -€1,110 to -€1,351 per share. Healthcare industry in France expected to see average net income growth of 22% next year. Consensus price target of €11,633 unchanged from last update. Share price fell 16% to €7.51 over the past week. Price Target Changed • Jul 30
Price target increased by 59% to €11,633 Up from €7,305, the current price target is an average from 3 analysts. New target price is 105,754% above last closing price of €10.99. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €1,110 compared to earnings per share of €131 last year. Major Estimate Revision • Jul 30
Consensus EPS estimates upgraded to €710 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€1,670 to -€710 per share. Revenue forecast unchanged from €5.45b at last update. Healthcare industry in France expected to see average net income growth of 25% next year. Consensus price target up from €7,305 to €11,633. Share price fell 16% to €10.99 over the past week. Announcement • Jul 27
emeis Société anonyme to Report First Half, 2024 Results on Oct 04, 2024 emeis Société anonyme announced that they will report first half, 2024 results on Oct 04, 2024 Price Target Changed • Jul 10
Price target increased by 12% to €12,300 Up from €10,975, the current price target is an average from 3 analysts. New target price is 104,492% above last closing price of €11.76. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €1,670 compared to earnings per share of €131 last year. Announcement • May 19
Orpea SA, Annual General Meeting, Jun 25, 2024 Orpea SA, Annual General Meeting, Jun 25, 2024. Location: 12 avenue marceau, paris France Major Estimate Revision • May 16
Consensus EPS estimates fall by 24% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€1,350 to -€1,670 per share. Revenue forecast of €5.63b unchanged since last update. Healthcare industry in France expected to see average net income growth of 31% next year. Consensus price target up from €10,975 to €11,725. Share price was steady at €13.98 over the past week. Reported Earnings • May 13
Full year 2023 earnings released: EPS: €0.13 (vs €62,330 loss in FY 2022) Full year 2023 results: EPS: €0.13 (up from €62,330 loss in FY 2022). Revenue: €5.20b (up 11% from FY 2022). Net income: €1.35b (up €5.38b from FY 2022). Profit margin: 26% (up from net loss in FY 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Healthcare industry in Europe. Price Target Changed • Apr 02
Price target increased by 71% to €6,230 Up from €3,643, the current price target is an average from 4 analysts. New target price is 61,352% above last closing price of €10.14. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €23,935 next year compared to a net loss per share of €62,330 last year. Price Target Changed • Mar 26
Price target increased by 71% to €6,230 Up from €3,643, the current price target is an average from 4 analysts. New target price is 52,288% above last closing price of €11.89. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €12,173 next year compared to a net loss per share of €62,330 last year. Price Target Changed • Feb 16
Price target increased by 39% to €5.45 Up from €3.91, the current price target is an average from 2 analysts. New target price is 42,478% above last closing price of €0.013. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €6.27 next year compared to a net loss per share of €62.33 last year. Announcement • Feb 08
Orpea SA has completed a Follow-on Equity Offering in the amount of €390.019673 million. Orpea SA has completed a Follow-on Equity Offering in the amount of €390.019673 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,324,787,415
Price\Range: €0.0133
Transaction Features: Rights Offering Announcement • Jan 18
Orpea SA announced that it expects to receive €390.019673 million in funding Orpea SA announced a private placement of 29,324,787,415 common shares at a price of €0.0133 per share for the gross proceeds of €390,019,672.62 on January 18, 2024. The transaction will include participation for €195.7 million from members of the Group by exercising their preferential subscription rights and €194.3 million by the members of SteerCo. As a part of the transaction, the company will pay €67 million to the financial restructuring and miscellaneous commissions. Announcement • Dec 27
Orpea Sa Appoints Méka Brunel as Independent Non-Executive Director Hammerson plc announces that Méka Brunel, independent non-executive director, was appointed as an independent non-executive director of ORPEA S.A. on 22 December 2023. Announcement • Dec 07
Orpea SA has filed a Follow-on Equity Offering in the amount of €1.2 billion. Orpea SA has filed a Follow-on Equity Offering in the amount of €1.2 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 67,415,730,337
Price\Range: €0.0178
Transaction Features: Rights Offering New Risk • Nov 30
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €1.18m (US$1.28m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Negative equity (-€1.8b). Market cap is less than US$10m (€1.18m market cap, or US$1.28m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (€56m net loss in 2 years). Buying Opportunity • Nov 30
Now 83% undervalued after recent price drop Over the last 90 days, the stock is down 99%. The fair value is estimated to be €0.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 15% in 2 years. Earnings is forecast to grow by 99% in the next 2 years. Announcement • Nov 15
Orpea SA has filed a Follow-on Equity Offering in the amount of €3.884212 billion. Orpea SA has filed a Follow-on Equity Offering in the amount of €3.884212 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 64,629,157,149
Price\Range: €0.0601
Transaction Features: Rights Offering Price Target Changed • Nov 14
Price target increased by 22% to €4.88 Up from €4.01, the current price target is an average from 4 analysts. New target price is 912% above last closing price of €0.48. Stock is down 94% over the past year. The company is forecast to post a net loss per share of €6.67 next year compared to a net loss per share of €62.33 last year. Announcement • Nov 14
Orpea SA, Annual General Meeting, Dec 22, 2023 Orpea SA, Annual General Meeting, Dec 22, 2023. Announcement • Nov 08
Orpea SA Provides Earnings Guidance for the Full Year 2023; Provides Consolidated Revenue Guidance for the Years 2024 and 2025 Orpea SA provided group earnings guidance for the full year 2023. For the full year 2023, Group revenue is expected to come in at around €5.2 billion, with an occupancy rate of 84.0% (versus 81.6% in 2022).Consolidated revenue would remain close to the amounts projected in the November 2022 Business Plan, at around €5.8 billion in 2024 and €6.1 billion in 2025, but on the basis of significantly different assumptions. Reported Earnings • Oct 23
First half 2023 earnings released: €5.74 loss per share (vs €4.17 loss in 1H 2022) First half 2023 results: €5.74 loss per share (further deteriorated from €4.17 loss in 1H 2022). Revenue: €2.54b (up 11% from 1H 2022). Net loss: €370.7m (loss widened 38% from 1H 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. New Risk • Oct 20
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€574m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€1.8b). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€574m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€79.0m market cap, or US$83.6m). New Risk • Oct 18
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €4.1b Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€1.8b). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (€79.5m market cap, or US$83.7m). Major Estimate Revision • Oct 13
Consensus EPS estimates fall by 22% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€4.45 to -€5.44 per share. Revenue forecast of €5.05b unchanged since last update. Healthcare industry in France expected to see average net income growth of 23% next year. Consensus price target of €3.91 unchanged from last update. Share price fell 19% to €1.13 over the past week. Announcement • Oct 06
Orpea SA to Report First Half, 2023 Results on Oct 11, 2023 Orpea SA announced that they will report first half, 2023 results on Oct 11, 2023 Major Estimate Revision • Sep 03
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€3.85 to -€4.45 per share. Revenue forecast unchanged at €5.06b. Healthcare industry in France expected to see average net income growth of 28% next year. Consensus price target of €3.91 unchanged from last update. Share price fell 5.0% to €1.67 over the past week. Major Estimate Revision • Aug 01
Consensus EPS estimates fall by 14% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€2.85 to -€3.24 per share. Revenue forecast of €5.13b unchanged since last update. Healthcare industry in France expected to see average net income growth of 23% next year. Consensus price target broadly unchanged at €3.94. Share price fell 6.7% to €1.74 over the past week. Announcement • Jul 28
An Unknown buyer acquired portfolio of four recently built retirement homes In Austria from Orpea SA (ENXTPA:ORP) for €55 million. An Unknown buyer acquired portfolio of four recently built retirement homes In Austria from Orpea SA (ENXTPA:ORP) for €55 million on June 30, 2023.
An Unknown buyer completed the acquisition of portfolio of four recently built retirement homes In Austria from Orpea SA (ENXTPA:ORP) on June 30, 2023. Announcement • Jul 13
Orpea SA Provides Financial Guidance for 2023 Orpea SA provided financial guidance for 2023. For the period Sales Growth Expected to Be Lower. Buying Opportunity • Jun 19
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 9.3%. The fair value is estimated to be €2.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 9.6% in a year. Earnings is forecast to grow by 95% in the next year. Reported Earnings • Jun 12
Full year 2022 earnings released: €62.33 loss per share (vs €1.01 profit in FY 2021) Full year 2022 results: €62.33 loss per share (down from €1.01 profit in FY 2021). Revenue: €4.68b (up 8.9% from FY 2021). Net loss: €4.03b (down €4.09b from profit in FY 2021). Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. Major Estimate Revision • May 16
Consensus EPS estimates fall by 374% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.439 to -€2.08 per share. Revenue forecast unchanged at €5.31b. Healthcare industry in France expected to see average net income growth of 20% next year. Consensus price target of €5.56 unchanged from last update. Share price was steady at €2.52 over the past week. Major Estimate Revision • Feb 03
Consensus EPS estimates fall by 25% The consensus outlook for fiscal year 2022 has been updated. 2022 expected loss increased from -€2.51 to -€3.13 per share. Revenue forecast unchanged at €4.67b. Healthcare industry in France expected to see average net income growth of 15% next year. Consensus price target down from €13.69 to €11.47. Share price fell 61% to €2.78 over the past week. Price Target Changed • Jan 23
Price target decreased by 21% to €13.69 Down from €17.42, the current price target is an average from 7 analysts. New target price is 96% above last closing price of €6.99. Stock is down 90% over the past year. The company is forecast to post a net loss per share of €2.51 compared to earnings per share of €1.01 last year. Buying Opportunity • Jan 12
Now 29% undervalued after recent price drop Over the last 90 days, the stock is down 33%. The fair value is estimated to be €10.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 7.8% in a year. Earnings is forecast to grow by 79% in the next year. Major Estimate Revision • Jan 08
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -€2.51 to -€1.51 per share. Revenue forecast steady at €4.68b. Healthcare industry in France expected to see average net income growth of 19% next year. Consensus price target of €17.17 unchanged from last update. Share price rose 6.7% to €6.58 over the past week. Price Target Changed • Nov 19
Price target decreased to €18.76 Down from €21.36, the current price target is an average from 7 analysts. New target price is 153% above last closing price of €7.40. Stock is down 91% over the past year. The company is forecast to post a net loss per share of €9.70 compared to earnings per share of €1.01 last year. Major Estimate Revision • Nov 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€2.37 to -€20.09 per share. Revenue forecast unchanged at €4.65b. Healthcare industry in France expected to see average net income growth of 14% next year. Consensus price target broadly unchanged at €21.21. Share price fell 5.4% to €7.56 over the past week. Price Target Changed • Nov 16
Price target decreased to €21.21 Down from €25.93, the current price target is an average from 7 analysts. New target price is 183% above last closing price of €7.49. Stock is down 92% over the past year. The company is forecast to post a net loss per share of €3.72 compared to earnings per share of €1.01 last year. Major Estimate Revision • Nov 09
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€2.29 to -€3.72 per share. Revenue forecast unchanged at €4.61b. Healthcare industry in France expected to see average net income growth of 16% next year. Consensus price target down from €25.93 to €21.36. Share price was steady at €8.31 over the past week. Price Target Changed • Nov 08
Price target decreased to €21.36 Down from €25.59, the current price target is an average from 7 analysts. New target price is 162% above last closing price of €8.15. Stock is down 91% over the past year. The company is forecast to post a net loss per share of €2.29 compared to earnings per share of €1.01 last year. Major Estimate Revision • Oct 13
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€2.08 to -€2.29 per share. Revenue forecast unchanged at €4.66b. Healthcare industry in France expected to see average net income growth of 18% next year. Consensus price target down from €28.68 to €25.59. Share price fell 2.3% to €10.24 over the past week. Major Estimate Revision • Oct 05
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€1.34 to -€2.08 per share. Revenue forecast unchanged at €4.65b. Healthcare industry in France expected to see average net income growth of 18% next year. Consensus price target down from €31.18 to €28.68. Share price fell 21% to €10.60 over the past week. Reported Earnings • Sep 29
First half 2022 earnings released: EPS: €0 (vs €1.59 in 1H 2021) First half 2022 results: EPS: €0 (down from €1.59 in 1H 2021). Revenue: €2.30b (up 11% from 1H 2021). Net loss: €269.0m (down 363% from profit in 1H 2021). Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Europe. Major Estimate Revision • Sep 13
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €1.72 to €1.48. Revenue forecast unchanged from €4.66b at last update. Net income forecast to grow 65% next year vs 23% growth forecast for Healthcare industry in France. Consensus price target down from €52.48 to €43.39. Share price fell 28% to €15.22 over the past week. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment deteriorated over the past week After last week's 22% share price decline to €16.45, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 14x in the Healthcare industry in Europe. Total loss to shareholders of 84% over the past three years. Price Target Changed • Sep 05
Price target decreased to €48.14 Down from €53.18, the current price target is an average from 8 analysts. New target price is 127% above last closing price of €21.20. Stock is down 80% over the past year. The company is forecast to post earnings per share of €1.75 for next year compared to €1.01 last year. Price Target Changed • Sep 01
Price target decreased to €50.01 Down from €55.40, the current price target is an average from 8 analysts. New target price is 140% above last closing price of €20.85. Stock is down 81% over the past year. The company is forecast to post earnings per share of €2.29 for next year compared to €1.01 last year. 
